UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | 0.87 | 0.87 |
| Q1 2022 | 2022-05-05 | 0.22 | 0.22 |
| Q4 2021 | 2022-02-28 | 0.55 | 0.55 |
| Q3 2021 | 2021-11-04 | -0.24 | -0.24 |
| Q2 2021 | 2021-08-04 | 0.02 | 0.02 |
| Q1 2021 | 2021-05-06 | 0.01 | 0.01 |
| Q4 2020 | 2021-02-25 | -0.14 | -0.14 |
| Q3 2020 | 2020-11-05 | 0.04 | -0.15 |
| Q2 2020 | 2020-08-06 | -0.53 | -0.53 |
| 2016-04-28 | Reiterated Rating | Cowen and Company | Buy | $60.00 |
| 2016-04-27 | Downgrade | RBC Capital | Outperform to Sector Perform | $48.00 to $17.00 |
| 2016-04-27 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $29.00 to $22.00 |
| 2016-04-27 | Downgrade | Royal Bank Of Canada | Outperform to Sector Perform | $48.00 to $17.00 |
| 2016-01-08 | Reiterated Rating | Cowen and Company | Buy | $60.00 |
| 2015-11-30 | Initiated Coverage | RBC Capital | Outperform | $48.00 |
| 2015-08-28 | Reiterated Rating | William Blair | Outperform | $42.00 |
| 2015-07-12 | Reiterated Rating | William Blair | Buy | $42.00 |
| 2015-06-26 | Reiterated Rating | William Blair | Outperform | $42.00 |
| 2015-03-23 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | |
| 2014-03-13 | Reiterated Rating | Jefferies Group | Buy | |
| 2013-11-25 | Upgrade | MLV & Co | Hold to Buy | $1.50 to $5 |
| 2013-11-25 | Upgrade | MLV & Co. | Hold to Buy | $1.50 to $5.00 |
| 2013-11-08 | Boost Price Target | Cowen and Company | Outperform | $5.78 to $6.00 |
| 2013-11-08 | Reiterated Rating | Jefferies Group | Buy | $3.00 |
| 2012-11-16 | Reiterated | MLV & Co | Buy | $10 to $7.50 |
| 2012-01-04 | Initiated | MLV & Co | Buy | $8 |
| 2010-11-08 | Initiated | Jefferies | Buy | $4 |
| 2010-05-13 | Upgrade | Wedbush | Neutral to Outperform | $2.60 to $6 |
| 2009-03-20 | Initiated | Wedbush Morgan | Buy | $1.20 |
| 2008-10-22 | Downgrade | Oppenheimer | Outperform to Perform | |
| 2008-05-19 | Reiterated | Susquehanna Financial | Positive | $7 to $5 |
| 2008-05-19 | Downgrade | Bear Stearns | Outperform to Peer Perform | |
| 2008-03-18 | Downgrade | Merriman Curhan Ford | Buy to Neutral | |
| 2008-02-22 | Upgrade | Oppenheimer | Perform to Outperform | $8.50 |
| 2007-10-03 | Initiated | Credit Suisse | Outperform | $8 |
| 2007-06-06 | Initiated | Susquehanna Financial | Positive | |
| 2007-02-26 | Downgrade | JMP Securities | Mkt Outperform to Mkt Perform |
| 2016-04-28 | Reiterated Rating | Cowen and Company | Buy | $60.00 |
| 2016-04-27 | Downgrade | RBC Capital | Outperform to Sector Perform | $48.00 to $17.00 |
| 2016-04-27 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $29.00 to $22.00 |
| 2016-04-27 | Downgrade | Royal Bank Of Canada | Outperform to Sector Perform | $48.00 to $17.00 |
| 2016-01-08 | Reiterated Rating | Cowen and Company | Buy | $60.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In DVAX 185 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 18.51M |
| FEDERATED INVESTORS INC /PA/ | 12.62M |
| STATE STREET CORP | 10.27M |
| Vanguard Group, Inc | 8.17M |
| Bain Capital Life Sciences Investors, LLC | 5.42M |
| Fisher Asset Management, LLC | 4.22M |
| Partner Fund Management, L.P. | 3.81M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.14M |
| GOLDMAN SACHS GROUP INC | 1.74M |
| Rock Springs Capital Management LP | 1.68M |
| BANK OF MONTREAL /CAN/ | 1.45M |
| Nuveen Asset Management, LLC | 1.42M |
| MORGAN STANLEY | 1.41M |
| Invesco Ltd. | 1.37M |
| NORTHERN TRUST CORP | 1.32M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| KESSEL MARK | 1.15% (3031431) | DVAX / OXGN / |
| DINA DINO CEO and Director | 0.19% (495771) | DVAX / |
| ORONSKY ARNOLD L | 0.14% (375055) | AGTC / DVAX / MGNX / TSRO / |
| MARTIN J TYLER President, CMO & Director | 0.08% (222089) | DVAX / |
| Gray Eddie CEO and Director | 0.06% (145210) | DVAX / |
| Phillips Peggy V | 0.05% (138023) | DVAX / PTLA / PZRX / TKMR / |
| TUCK STEPHEN F VP, Global Technical Ops | 0.04% (106151) | DVAX / |
| Janssen Robert Chief Medical Officer and VP | 0.03% (74547) | DVAX / |
| OSTRACH MICHAEL S VP, CBO, and General Counsel | 0.02% (61215) | DVAX / |
| COFFMAN ROBERT Chief Scientific Officer & VP | 0.02% (55955) | DVAX / |
| Johnson David Louis Vice President & CAO | 0.01% (21697) | DVAX / |
| CANO FRANCIS | 0.01% (20000) | BMRA / DVAX / |
| KISNER DANIEL L | 0.01% (15000) | CNAT / DVAX / LPTN / TKMR / |
UM